Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 38

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 38
---
 LLP as to matters of United States federal law and New York State law. Certain Japanese legal matters will be passed upon for us by Nishimura & Asahi (Gaikokuho Kyodo Jigyo). The validity of the Notes and the Guarantee will be passed upon for any underwriters, dealers or agents by Simpson Thacher & Bartlett LLP as to matters of United States federal law and New York State law.

### WHERE YOU CAN FIND MORE INFORMATION

#### Available Information
This prospectus supplement is part of a registration statement that we filed with the SEC. The registration statement, including the attached exhibits, contains additional relevant information about Takeda. The rules and regulations of the SEC allow us to omit some of the information included in the registration statement from this prospectus supplement. Takeda is subject to the information requirements of the Exchange Act and, in accordance with the Exchange Act, files annual reports, special reports and other information with the SEC. The SEC maintains an internet site at http://www.sec.gov that contains reports, proxy and information statements and other information about issuers, like Takeda, that file electronically with the SEC. Takeda’s corporate website is http://www.takeda.com.

Takeda is currently exempt from the rules under the Exchange Act that prescribe the furnishing and content of proxy statements, and its officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Takeda is not required under the Exchange Act to publish financial statements as frequently or as promptly as are U.S. companies subject to the Exchange Act. Takeda will, however, continue to furnish its shareholders with annual reports containing audited financial statements and will issue interim press releases containing unaudited results of operations as well as such other reports as may from time to time be authorized by it or as may be otherwise required.

Takeda’s American Depositary Shares are listed on the New York Stock Exchange under the trading symbol “TAK.”

#### Incorporation by Reference
The SEC’s rules allow us to incorporate by reference information into this prospectus supplement. The information incorporated by reference is considered to be a part of this prospectus supplement, and information that Takeda files later with the SEC will automatically update and supersede this information. This prospectus supplement incorporates by reference Takeda’s annual report on Form 20-F for the fiscal year ended March 31, 2025 filed with the SEC on June 25,